Trial Profile
A Phase II Trial of Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Pevonedistat (Primary)
- Indications Myelodysplastic syndromes; Myeloproliferative disorders
- Focus Therapeutic Use
- 12 Feb 2024 Planned End Date changed from 1 Jan 2024 to 3 Oct 2024.
- 17 Nov 2023 Planned End Date changed from 1 Sep 2023 to 1 Jan 2024.
- 20 Jun 2022 Planned End Date changed from 1 Jul 2023 to 1 Sep 2023.